Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis

Summary Treatment with zoledronic acid 5 mg maintained bone turnover markers in the premenopausal range, increased lumbar spine bone mineral density, and maintained hip bone mineral density in women previously treated with odanacatib 50 mg weekly.